WSG Westdeutsche Studiengruppe GmbH

7 trials 3 recruiting Commercial sponsor

Filter these 7 trials by condition, phase, country and more.

Open in Search →

7 Registered trials

3 Recruiting

3 Completed trials

6 Countries active

7 Unique IMPs

100% Results reported

Phase III

Phase II

Phase III: 5 Phase II: 2

Oversight events:

3 serious breaches 2 urgent safety measures across 3 trials

View oversight register →

100%

3 of 3 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Breast cancer female 7 Breast cancer 5 Hormone receptor positive breast cancer 4 Breast cancer male 3 Triple negative breast cancer 2 Hormone receptor positive HER2 negative breast cancer 2 Breast cancer stage II 1 Breast cancer stage I 1 HER2 positive breast cancer 1

Top IMPs

PEMBROLIZUMAB 2 RIBOCICLIB 2 SACITUZUMAB GOVITECAN 2 CAPIVASERTIB 1 ELACESTRANT 1

All trials

7 total

NeoAdjuvant Dynamic marker - Adjusted Personalized Therapy comparing sacituzumab govitecan+pembrolizumab vs. SoC chemotherapy in clinical st… Pending

2024-516734-35-00 Phase III 1 country PEMBROLIZUMAB; SACITUZUMAB GOVITECAN
Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing adjuvant Elacestrant with standard endocrine treatment in genomically and/… Recruiting

2025-522484-15-00 Phase III 3 countries ELACESTRANT; RIBOCICLIB
A clinical study to evaluate the safety, efficacy, and impact on quality of life of capivasertib alongside routine endocrine treatment in pa… Recruiting

2024-511392-15-00 Phase III 3 countries CAPIVASERTIB
NeoAdjuvant study comparing sacituzumab govitecan versus sacituzumab govitecan+pembrolizumab treatment in low-risk, triple-negative early br… Recruiting

2023-508787-29-00 Phase II 1 country PEMBROLIZUMAB; SACITUZUMAB GOVITECAN
NeoAdjuvant Dynamic marker - Adjusted Personalized Therapy comparing trastuzumab-deruxtecan versus pacli-/docetaxel+carboplatin+trastuzumab+… Ended

2024-514458-61-01 Phase II 1 country
A randomized, controlled, open-label, phase III-trial on Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing abemaciclib combi… Ended

2023-509242-35-00 Phase III 3 countries
Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing endocrine therapy plus ribociclib versus chemotherapy in intermediate-risk… Ended

2024-515769-32-00 Phase III 1 country RIBOCICLIB

Showing 1–7 of 7 trials

← All sponsors A–Z